| P50 | author | Pei-Wen Hsiao | Q40066871 |
| P2093 | author name string | Chi-Hsien Chan | |
| | Chia-Ho Kuo | |
| | Chia-Ying Wu | |
| | Chien-Hung Pan | |
| | Ching-Chuan Chang | |
| | Chung-Cheng Liu | |
| | Hsiu-Fen Tai | |
| | Juine-Ruey Chen | |
| | Wan-Hsin Liu | |
| | Yen-Hung Chow | |
| | Yi-Wen Lin | |
| | Yung-Tsung Chen | |
| P2860 | cites work | New low-viscosity overlay medium for viral plaque assays | Q21245137 |
| | Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People's Republic of China | Q24535192 |
| | Production of EV71 vaccine candidates | Q26866091 |
| | Immunological and biochemical characterization of coxsackie virus A16 viral particles | Q28485432 |
| | Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates | Q31056961 |
| | Hand, foot, and mouth disease in China, 2008-12: an epidemiological study | Q33668897 |
| | Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene | Q33725572 |
| | Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems. | Q33809953 |
| | An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. | Q33875086 |
| | Neurologic complications in children with enterovirus 71 infection | Q33875092 |
| | Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. | Q33908518 |
| | An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China | Q33911890 |
| | Long-term immunogenicity studies of formalin-inactivated enterovirus 71 whole-virion vaccine in macaques | Q34149853 |
| | High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. | Q51143326 |
| | Epidemic characteristics of hand, foot, and mouth disease in Shanghai from 2009 to 2010: Enterovirus 71 subgenotype C4 as the primary causative agent and a high incidence of mixed infections with coxsackievirus A16 | Q57096427 |
| | Application of a serum-free medium for the growth of Vero cells and the production of reovirus | Q73066445 |
| | Selection and characterization of vaccine strain for Enterovirus 71 vaccine development | Q82811412 |
| | Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection | Q86408467 |
| | Coxsackievirus A16: epidemiology, diagnosis, and vaccine | Q34290731 |
| | Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Q34347924 |
| | Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. | Q34603659 |
| | An overview of the evolution of enterovirus 71 and its clinical and public health significance | Q34635602 |
| | The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children | Q35048558 |
| | Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers | Q35053266 |
| | A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection | Q35702513 |
| | A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection | Q35826494 |
| | Human enterovirus 71 epidemics: what's next? | Q37168703 |
| | Progress on the research and development of inactivated EV71 whole-virus vaccines | Q37530094 |
| | Development of enterovirus 71 vaccines. | Q37682898 |
| | EV71: an emerging infectious disease vaccine target in the Far East? | Q37715371 |
| | Neural pathogenesis of enterovirus 71 infection | Q37720283 |
| | Virology, epidemiology, pathogenesis, and control of enterovirus 71. | Q37801742 |
| | Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials | Q38195326 |
| | Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases | Q38248866 |
| | Review of enterovirus 71 vaccines | Q38263484 |
| | An inactivated enterovirus 71 vaccine in healthy children | Q40216677 |
| | Complete genome analysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14 years | Q41859348 |
| | A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses | Q42222745 |
| | Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China | Q42226974 |
| | Enterovirus 71 related severe hand, foot and mouth disease outbreaks in South-East Asia: current situation and ongoing challenges | Q42588563 |
| | Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system | Q44285689 |
| | Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development | Q45056729 |
| | Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus | Q45734536 |
| | Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants. | Q45963384 |
| | Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema | Q48235723 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bioreactor | Q864699 |
| | virology | Q7215 |
| P304 | page(s) | e0136420 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Inactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic Mouse | |
| P478 | volume | 10 | |